Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | OPA1 | O60313 | 1/20 | 0.37 |
| ▸ | EIF5B | O60841 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12312046 | 0.99 | HTR2A (0.59) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL2260014 | 0.96 | HTR2A (0.65) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL9303578 | 0.84 | HTR2A (0.63) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL2345293 | 0.83 | HTR2A (0.70) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL12572732 | 0.82 | HTR2A (0.60) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL1395857 | 0.80 | MTNR1A (0.61) | HTR2AHTR2CMTNR1AMTNR1BGAA | |
| SCHEMBL9079125 | 0.78 | HTR2A (0.89) | HTR2AHTR2CMTNR1AMTNR1B | |
| SCHEMBL2348471 | 0.78 | HTR2A (0.52) | HTR2AHTR2CMTNR1AMTNR1BMEN1 | |
| SCHEMBL2261530 | 0.78 | HTR2A (0.48) | HTR2AHTR2CMTNR1AMTNR1BMCL1 | |
| SCHEMBL15024522 | 0.77 | HTR2A (0.69) | HTR2AHTR2CMTNR1AMTNR1BMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | HTR2A 4336/4885HTR2C 4346/4885MTNR1A 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.